Newsroom - ARTES Biotechnology GmbH

Press releases

ARTES Biotechnology received next grant of patent for METAVAX®

, Biotechnology

ARTES Biotechnology specialized in microbial process development and technology transfer for pharmaceutical industry is pleased to announce a...

ARTES and BioSun announce co-development for HPV vaccine

, Biotechnology

ARTES Biotechnology and BioSun Pharmed announced to join forces for the development and manufacturing of a HPV (human papilloma virus) vaccine...

ARTES and Burnet Institute join forces to develop novel hepatitis C vaccine

, Biotechnology

ARTES Biotechnology and Burnet Institute announce they have joined forces to develop a novel, effective vaccine to prevent transmission of hepatitis...

ARTES Biotechnology and Biosphere announce collaboration

, Biotechnology

ARTES Biotechnology, specialized in microbial cell line and process development for recombinant protein production and technology provider for...

ARTES Biotechnology and Boehringer Ingelheim Animal Health Announce Collaboration

, Cooperations / Mergers

ARTES Biotechnology, specialized in recombinant protein production, process and vaccine development from microbial expression systems announces...

ARTES Biotechnology, instrAction and Q-Biologicals Join Forces for Veterinary Vaccine Development

, Biotechnology

B3C newswire / -[/b] ARTES Biotechnology, InstrAction and Q-Biologicals establish a three-party consortium for vaccine developments for veterinary...

Malaria Transmission-blocking Vaccines

, Biotechnology

. - ARTES Biotechnology and Burnet Institute have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria...

ARTES Biotechnology and Bio Farma Announce Collaboration in Vaccine Development

, Biotechnology

ARTES and Bio Farma announced today to join forces for the development and manufacturing of vaccine candidates. The agreed collaboration involved...

ARTES Biotechnology and Midas Pharma signed Cooperation Contract

, Biotechnology

ARTES Biotechnology announced the collaboration with Midas Pharma for strategic marketing opportunities. Aim of the cooperation is the finding...

ARTES Biotechnology issued New Patent in Australia for VLP Technology

, Biotechnology

ARTES Biotechnology specialized in microbial cell line and process development as well as in technology transfer for pharmaceutical industry...

Strategic cooperation between ARTES Biotechnology and PAC

, Biotechnology

Artes and PAC join forces and combine their technologies and know-how. ARTES Biotechnology specializes in recombinant protein production, process...

ARTES Announces a Strategic Collaboration Deal for Vaccine Development

, Biotechnology

ARTES Biotechnology, specialized in recombinant protein production and process development in microbial expression systems, started a development...

ARTES Steps Further Into the Vaccine Business by Acquiring Anavax

, Biotechnology

ARTES Biotechnology announces today the acquirement of the ANAVAX virus-like particle (VLP) technology from Select Vaccines Ltd. ANAVAX is a...

Injectable Sustained Release Formulations of Therapeutic Proteins

, Biotechnology

Q Chip Ltd and ARTES Biotechnology GmbH announce that they have signed a Collaborative Agreement to explore the co-development of a new sustained...

Erfolgreiche Zusammenarbeit zwischen ARTES und Rhein Minapharm wird fortgeführt

, Company-internal

ARTES Biotechnology GmbH, Spezialist für die Entwicklung rekombinanter Proteine und Prozesse in Hefen, und Rhein Minapharm Biogenetics, eine...

Media

Loading data, please wait...
Loading data, please wait...
Loading data, please wait...
Loading data, please wait...
ARTES Biotechnology GmbH
Elisabeth-Selbert-Str. 9
D - 40764 Langenfeld




Contact

Frau Dr. Melanie Piontek


Business Development Director
ARTES Biotechnology

Phone +49 2173 2758712

Herr Dr Ali Eram


Commercial Manager

Phone +98 2188219500 2

all contacts

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.